Performance of Common Genetic Variants in Breast-cancer Risk Models

BACKGROUND Genomewide association studies have identified multiple genetic variants associated with breast cancer. The extent to which these variants add to existing risk-assessment models is unknown. METHODS We used information on traditional risk factors and 10 common genetic variants associated with breast cancer in 5590 case subjects and 5998 control subjects, 50 to 79 years of age, from four U.S. cohort studies and one case-control study from Poland to fit models of the absolute risk of breast cancer. With the use of receiver-operating-characteristic curve analysis, we calculated the area under the curve (AUC) as a measure of discrimination. By definition, random classification of case and control subjects provides an AUC of 50%; perfect classification provides an AUC of 100%. We calculated the fraction of case subjects in quintiles of estimated absolute risk after the addition of genetic variants to the traditional risk model. RESULTS The AUC for a risk model with age, study and entry year, and four traditional risk factors was 58.0%; with the addition of 10 genetic variants, the AUC was 61.8%. About half the case subjects (47.2%) were in the same quintile of risk as in a model without genetic variants; 32.5% were in a higher quintile, and 20.4% were in a lower quintile. CONCLUSIONS The inclusion of newly discovered genetic factors modestly improved the performance of risk models for breast cancer. The level of predicted breast-cancer risk among most women changed little after the addition of currently available genetic information.

[1]  J. Tukey One Degree of Freedom for Non-Additivity , 1949 .

[2]  W. Willett,et al.  Moderate alcohol consumption and the risk of breast cancer. , 1987, The New England journal of medicine.

[3]  M. Gail,et al.  Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.

[4]  J. Benichou,et al.  Epidemiology and Biostatistics Program of the National Cancer Institute , 1994 .

[5]  J Benichou,et al.  Validation studies for models projecting the risk of invasive and total breast cancer incidence. , 1999, Journal of the National Cancer Institute.

[6]  M H Gail,et al.  Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. , 1999, Journal of the National Cancer Institute.

[7]  J. Gohagan,et al.  Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. , 2000, Controlled clinical trials.

[8]  Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast Cancer. , 2000, Journal of the National Cancer Institute.

[9]  Carmen Rodriguez,et al.  The American Cancer Society Cancer Prevention Study II Nutrition Cohort , 2002, Cancer.

[10]  R. Langer,et al.  The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. , 2003, Annals of epidemiology.

[11]  M. Thun,et al.  The American Cancer Society Cancer Prevention Study II Nutrition Cohort , 2002, Cancer.

[12]  Jinbo Chen,et al.  Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. , 2006, Journal of the National Cancer Institute.

[13]  N. Chatterjee,et al.  Powerful multilocus tests of genetic association in the presence of gene-gene and gene-environment interactions. , 2006, American journal of human genetics.

[14]  S. Chanock,et al.  Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses , 2006, Human Genetics.

[15]  W. Willett,et al.  A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer , 2007, Nature Genetics.

[16]  Lester L. Peters,et al.  Genome-wide association study identifies novel breast cancer susceptibility loci , 2007, Nature.

[17]  Jose Jeronimo,et al.  Human papillomavirus and cervical cancer , 2007, The Lancet.

[18]  Francis S Collins,et al.  A HapMap harvest of insights into the genetics of common disease. , 2008, The Journal of clinical investigation.

[19]  M. Gail Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. , 2008, Journal of the National Cancer Institute.

[20]  Olle Melander,et al.  Polymorphisms associated with cholesterol and risk of cardiovascular events. , 2008, The New England journal of medicine.

[21]  B. Ponder,et al.  Polygenes, risk prediction, and targeted prevention of breast cancer. , 2008, The New England journal of medicine.

[22]  R. Wilkins Polygenes, risk prediction, and targeted prevention of breast cancer. , 2008, The New England journal of medicine.

[23]  Peter Almgren,et al.  Clinical risk factors, DNA variants, and the development of type 2 diabetes. , 2008, The New England journal of medicine.

[24]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[25]  K. Narayan,et al.  Clinical risk factors, DNA variants, and the development of type 2 diabetes. , 2009, The New England journal of medicine.

[26]  Gynecologists ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. , 2009, Obstetrics and gynecology.

[27]  Timothy J Wilt,et al.  Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. , 2009, Annals of internal medicine.

[28]  S. Wacholder,et al.  Risk estimation for the next generation of prevention programmes for cervical cancer. , 2009, The Lancet. Oncology.

[29]  M. Thun,et al.  Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2 , 2009, Nature Genetics.

[30]  M. Gail Value of adding single-nucleotide polymorphism genotypes to a breast cancer risk model. , 2009, Journal of the National Cancer Institute.

[31]  W. Willett,et al.  A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1) , 2009, Nature Genetics.

[32]  Peter Kraft,et al.  Beyond odds ratios — communicating disease risk based on genetic profiles , 2009, Nature Reviews Genetics.

[33]  W. Willett,et al.  A genome-wide association study identifies alleles in FGFR 2 associated with risk of sporadic postmenopausal breast cancer , 2012 .